Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASGR1 | P07306 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13641157 | 1.00 | ASGR1 (0.33) | ASGR1CA14CCR5HSD11B1SSTR4 | |
| SCHEMBL15285331 | 0.94 | CA14 (0.36) | ASGR1CA14CCR5HSD11B1SSTR4 | |
| SCHEMBL2660690 | 0.88 | CA14 (0.33) | ASGR1CA14CCR5HSD11B1SSTR4 | |
| SCHEMBL1238808 | 0.88 | CA14 (0.33) | ASGR1CA14CCR5HSD11B1SSTR4 | |
| SCHEMBL10323856 | 0.87 | CA14 (0.34) | ASGR1CA14HSD11B1SSTR4DPP4 | |
| SCHEMBL1067463 | 0.86 | EPHX1 (0.36) | CA14HSD11B1DPP4 | |
| SCHEMBL4914499 | 0.84 | CA14 (0.37) | ASGR1CA14CCR5HSD11B1SSTR4 | |
| SCHEMBL20674336 | 0.83 | SLC6A4 (0.35) | CA14CHRM3 | |
| SCHEMBL4711748 | 0.83 | CA14 (0.39) | ASGR1CA14CCR5HSD11B1DPP4 | |
| SCHEMBL8218482 | 0.82 | NFKB1 (0.34) | ASGR1CA14CCR5HSD11B1SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3239154-A1 | IRAK INHIBITORS AND USES THEREOF | Nimbus Iris, Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-2663312-B1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS INC (US) | 2017-10-11 | — | — | EP | disclosed |
| US-20160296524-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS INC (US) | 2016-10-13 | — | — | US | disclosed |
| US-9340554-B2 | IRAK inhibitors and uses thereof | NIMBUS IRIS, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150025093-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2015-01-22 | — | — | US | disclosed |
| US-8703941-B2 | IRAK inhibitors and uses thereof | NIMBUS IRIS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| EP-2663312-A1 | IRAK INHIBITORS AND USES THEREOF | Nimbus Iris, Inc. (US) | 2013-11-20 | — | — | EP | disclosed |
| US-20120283238-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| WO-2012097013-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2012-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025093-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ASGR1 2832/4885CA14 4834/4885CCR5 477/4885 |
| US-20160296524-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ASGR1 2832/4885CA14 4834/4885CCR5 477/4885 |
| US-20120283238-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ASGR1 2832/4885CA14 4834/4885CCR5 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.